Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ImpediMed Announces Appointment of Managing Director and CEO (ASX:IPD)

ImpediMed Limited (“ImpediMed” or “the Company”) is pleased to announce the appointment of Richard Valencia as Managing Director and Chief Executive Officer (MD & CE...read more

ImpediMed announces management reorganisation (ASX:IPD)

Key Takeaways Management reorganisation, resulting in CEO direct reports consolidated down to four key management roles Expanded role for Dr Thomas Schenk as Chief Medical Offic...read more

ImpediMed - AstraZeneca Further Extends Clinical Trial Contract (ASX:IPD)

Key Highlights AstraZeneca extends its contract for a Phase IIb trial, which utilises 210 SOZO® devices to measure fluid volume in patients with chronic kidney disease, for an add...read more

ImpediMed - Appendix 4C & Quarterly Activities Report - Sep-22 Qtr (ASX:IPD)

To view the report, download the attached PDF.

ImpediMed - New Corporate Oncology Account with GenesisCare (ASX:IPD)

ImpediMed Limited (ASX.IPD) is pleased to announce the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare. The pilot program will consist of an initial roll out ...read more

Notification of cessation of securities - IPD (ASX:IPD)

To view the notification, download the attached PDF.

ImpediMed - 2022 Annual Report & Annual General Meeting Date (ASX:IPD)

ImpediMed Limited (ASX: IPD, ImpediMed or Company) is pleased to release its Annual Report for the year ended 30 June 2022. ImpediMed advises that its 2022 Annual General Meeting will be held on ...read more

ImpediMed - Appendix 4G and Corporate Governance Statement (ASX:IPD)

To view the appendix, download the attached PDF.

ImpediMed - Appendix 4E (ASX:IPD)

To view the appendix, download the attached PDF.

ImpediMed - Appendix 4C & Quarterly Activities Report - Jun-2022 Qtr (ASX:IPD)

To view the report, download the attached PDF.

ImpediMed CEO Announces Departure (ASX:IPD)

ImpediMed Limited (ASX:IPD) (ImpediMed, Company) announced today that Managing Director and Chief Executive Officer (CEO) Richard Carreon would be stepping down from the Company effective close of b...read more

ImpediMed - Lymphoedema Risk Factors Paper Published (ASX:IPD)

ImpediMed Limited (ASX:IPD) (ImpediMed) is pleased to announce the publication of a paper on the risk factors for breast cancer related lymphoedema. The paper was published in Cancer, an internation...read more

ImpediMed - Appendix 4C & Quarterly Activities Report (ASX:IPD)

To view the report, download the attached PDF.

ImpediMed - AstraZeneca extends and increases Renal Contract (ASX:IPD)

Key Highlights * AstraZeneca extends its second contract for a Phase IIb trial, which is utilising SOZO® to measure fluid volume in patients with chronic kidney disease, by 3 months. * In ad...read more